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Lanthanide bioprobes and bioconjugates are ideal luminescent stains in view of
their low propensity to photobleaching, sharp emission lines and long excited
state lifetimes permitting time-resolved detection for enhanced sensitivity.
We show here how the interplay between physical, chemical and biochemical
properties allied to microfluidics engineering leads to self-assembled dinuclear
lanthanide luminescent probes illuminating live cells and selectively detecting
biomarkers expressed by cancerous human breast cells.1. Introduction
A key challenge in biology and medicine is to gain information on the structural
and functional properties of cells, organs and living organisms. Imaging
techniques are crucial tools towards this goal, and the development of trustable
diagnostic imaging techniques such as positron emission tomography, X-ray
computed tomography, X-ray angiography, magnetic resonance imaging or
ultrasound imaging, and of their associated contrast agents, has had a tremen-
dous impact on the progress of medicine over the past 30 years, particularly
with respect to cancer detection and treatment. Despite the impressive panoply
of available high-tech imaging tools, there is still much space for improvements,
especially when it comes to spatial resolution, sensitivity and penetration depth.
Present efforts focus on several aspects, for instance, theranostics which combi-
nes drug delivery with a diagnostic agent [1] or molecular imaging which
aims at gaining target-specific information with high sensitivity. To fulfil the
requirements associated with these technologies, it appears necessary to design
probes mixing different modalities and/or signal processing protocols [2].
Luminescence imaging emerges as an essential component among the
various technologies required to meet the stringent constraints of modern diag-
nostics and therapy [3,4]. Indeed, depending on its wavelength, light can
penetrate deeply within biological tissues and its detection is highly sensitive,
because single-photon spectroscopy is achievable. Another advantage is that
photons interact with electrons at the molecular level and techniques such as
Fo¨rster resonant energy transfer (FRET) lead to sensitive detection of molecular
interactions, for example, DNA hybridization or biomarker recognition. More-
over, depending on the lifetime of the excited state generating light, time-
domain information can be gained, thanks to time-gated detection. Finally,
because quantum yields are temperature-dependent, recording of luminescence
intensity variations within cells or tissues results in thermal sensing and/or
imaging [5]. There are essentially four types of optical luminescent bioprobes.
(i) The first category consists of well-documented and highly fluorescent
organic luminophores which are easy to derivatize for gaining specificity,
for example, cell-penetrating agents localizing in given organelles or
bioconjugated chromophores for antigen detection. Two major disadvan-
tages of organic chromophores are their very short excited state lifetimes
and their sensitivity to photobleaching. The first drawback renders time-
resolved detection (TRD), which considerably enhances signal-to-noise
ratio (SNR) byoffsetting the probe autofluorescence, difficult to implement,
because it necessitates sophisticated and expensive experimental set-ups.
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which can be as short as a few seconds only, a rather
small time window for informative imaging.
(ii) Fluorescent proteins, of which the archetype is the
green fluorescent protein discovered inAequorea victoria
medusa, which emits at 505 nm, and which revolutio-
nized microscopy [6,7]. The main advantages of this
protein are its low phototoxicity when compared with
small organic molecules such as fluorescein isothiocya-
nate, and the fact that derivatives (mutants, fusion with
other proteins) can be easily engineered, leading to
specific detection. On the other hand, it suffers the
same problems outlined above for organic dyes and,
in addition, its large size may hinder protein–protein
interactions in cellular environments [8].
(iii) A second type of chromophores encompasses semicon-
ductor quantum dots (QDs) and their bioconjugates
which are becoming a dominant class of imaging
probes. QDs are highly luminescent with fairly sharp
(fullwidth at half height (fwhh) of 25–100 nm) emission
bands ranging from 450 to 1250 nm depending on the
nanocrystal size and they display better photostability
than organic chromophores [9]. The disadvantages evi-
denced in the early experiments, namely large particle
size (10–30 nm) and blinking behaviour which inter-
rupts fluorescence for variable times, have the
tendency to be cured presently, thanks to better syn-
thetic methods [10]. On the other hand, concerns
about toxicity of the heavy elements they are made of
and of the free radicals generated consecutively to
their use remain present [11].
(iv) Finally, d-transition metal ions [12,13] and trivalent
lanthanide ions, LnIII [14,15], represent valuable substi-
tutes to both organic luminophores and QDs. This
originates from their remarkable optical properties,
featuring long excited state lifetimes and, for LnIII deriva-
tives, narrow absorption and emission bands with
energies showing small dependence on the chemical
environment of the ion. As a result, LnIII ions have been
taken advantage of in numerous applications [16], in par-
ticular, in biosciences. Indeed, both spectral and time
discrimination of their emission bands, which extend
from UV through near-infrared (NIR) spectral ranges
depending on the ion, can be implemented with basic
and low-cost instrumentation. Another noteworthy and
decisive advantage of lanthanide compounds is their
low sensitivity to photobleaching, because their lumines-
cence is sensitized via the organic ligands and energy
transfer from the chromophore to the LnIII ion is fast
enough to avoid photodegradation of the ligand [17].
While nanoparticles and nanocomposites are rapidly
changing the landscape of bioreporters for sensing and
imaging [18],molecular complexes remain inwidespread
use, and, in the following sections, we exclusively focus
on the latter bioprobes and their conjugates.
The use of time-resolved luminescence (TRL) coupled with
lanthanide probes for bioanalyses was pioneered by Hemmila¨
and co-workers [19,20] at the end of the 1970s who proposed
to replace radioactivity-based immunoassays with lumines-
cence immunoassays. These analyses are now ubiquitous in
medical and biological laboratories. Examples are testing for
early stage of pregnancy by quantifying the human chorionicgonadotropin hormone, detecting the human immunodefi-
ciency virus, or measuring the prostate-specific antigen level
in blood or urine. Lanthanide complexes, polyaminocarboxy-
lates or macrocyclic complexes, are attached onto a specific
antibody, and luminescence from the emitting ion is detected
after the biochemical reaction is completed, either in a two-step
procedure (heterogeneous assays) or with a one-step, FRET-
based, protocol (homogeneous assays) [15]. The field is the
subject of numerous review articles appearing regularly
[15,21] and it has sustained an unprecedented growth with
the appearance of nanoprobes [22]. Initially, LnIII ions or com-
plexes were simply doped into silica nanoparticles further
derivatized with avidin, biotin or an antibody [23]. However,
the need for UV/blue excitation which may be detrimental
to live cells has led to the development of bioprobes based
on upconversion nanoparticles (UCNPs) [24,25]. The latter
usually consist of a sensitizer, typically YbIII absorbing at
980 nm, that is at a wavelength at which biological tissues
are transparent, and of an emitter such as ErIII or TmIII with
luminescence in the visible or onset of the NIR spectral
ranges; the upconverting nanophosphors can also be provided
in light-responsive systems which release payloads upon NIR
excitation [26]. Alternatively, long-persistence luminescent
nanophosphors have lifetimes long enough so that excitation
may be conducted prior to the introduction of the biolabel
into the sample to be assayed or imaged [27].
As the success story of lanthanide-based bioanalyses
unfolded, attempts to use these probes for bioimaging were
a logical follow up. Attention has been focused on both
in vitro and in vivo imaging, and several solutions have
been proposed for improving the SNR of the images. In the
case of in vivo imaging, probes excitable and emitting in the
NIR have been proposed, e.g. NdIII-doped NaGdF4 nanopar-
ticles [28] or YbIII complexes amenable to multi-photon
excitation [29]. On the other hand, in vitro imaging or sensing,
particularly of fixed cells or tissues, is less compelling with
respect to phototoxicity and many lanthanide coordination
compounds revealed to be efficient ‘optical contrast agents’
[30,31]; the luminosity of such probes can be increased if
dendrimeric ligands are used [32].
In this review, we concentrate on one class of luminescent
lanthanide bioprobes, namely dinuclear helicates which meet
the chemical, physical and biochemical requirements for
in vitro staining of live cells and for the detection of biomarkers.
We show how combining TRD with laboratory-on-a-chip tech-
nology leads to highly sensitive and selective recognition of
biomarkers expressed by human cancerous cells and tissues.2. Time-resolved luminescence microscopy
Intrinsically, quantitative measurement of luminescence inten-
sity is more sensitive than measurement of light absorption,
especially when weak signals are concerned. Very sensitive
photomultipliers operated in photon-counting mode, or CCD
cameras detect a few photons per second when the dark
noise is reduced by cooling the photocathode. With respect
to microscopy, luminescence recording of the image results
in enhanced contrast, comparable with the one obtained by
conventional techniques associated with classical optical
microscopy, for example, oblique, cross-polarized or darkfield
illumination. In luminescence microscopy, luminescent stains
are introduced into the sample, and emission is stimulated
sample
dichroic
mirror
light
source
excitation filter
objective
detector
ocular
emission filter
Figure 1. Simplified scheme of an epifluorescence microscope used for lumi-
nescence microscopy.
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organic molecules, phosphorescent transition metal com-
plexes, QDs, doped nanoparticles or their bioconjugates for
improved specificity. However, staining may interfere with
the cell functions or even may need fixing the cells; in any
case, cytotoxicity and morphology tests should be performed
to detect unwanted effects.
In life sciences, the experimental set-up corresponds
usually to an epifluorescence microscope in which the excitation
light is directed onto the sample from above after going
through a dichroic mirror and the objective (figure 1). The exci-
tation wavelength is selected through adequate choices of the
dichroic mirror and the excitation filter. The light emitted by
the sample is focused onto the detector through the objective
used for excitation, and the spectral range is selected by the
emission filter. A great deal of the excitation light is transmitted
by the sample, so that only reflected light accompanies sample
fluorescence, and the SNR is large, especially that the emission
filter can help eliminate spurious excitation light. The light
source can be non-coherent (e.g. xenon lamp) or coherent
(e.g. laser, diode laser), polarized or un-polarized depending
on the effect sought for.
The photometric throughput of a luminescence microscope
is estimated as follows assuming linear isotropic response and
not too intense illumination to avoid saturation [33]. Excitation
light with wavelength l is absorbed by the chromophores in
the object field with a probability governed by the absorption
cross section sA(l) (in cm
2 molecule21) defined as
sAðlÞ ¼ 103 lnð10Þ1lN ¼ 3:82 10
21 1ðlÞ; ð2:1Þ
where 1(l) is the molar absorption coefficient (M21 cm21) and
NAvogadro’s number (molecule mol21). The usefulness of the
cross section is easy to understand: it avoids defining an
absorption path length in the sample. In addition to 1(l), chro-
mophores are characterized by their quantum yield Q(lexc, l)and act as secondary isotropic light sources with spectral radi-
ant intensity I(l):
IðlÞ ¼ IexcðlÞsAðlÞQðlexc; lÞqðlÞ
4p
; ð2:2Þ
where Iexc(l) is the excitation irradiance (W cm
22), and q(l) is
the spectral distribution function, which is related to the emis-
sion spectrum corrected for the instrumental function, Icorr(l):
qðlÞ ¼ lIcorrðlÞÐ
lIcorrðlÞdl : ð2:3Þ
Calculation of the signal intensity at the detector must take
into account the solid angle of collection for the chromophore
embedded into a medium with refractive index n and acting
as a non-Lambertian diffuse point source. This solid angle is
equal to
2p 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 NA
n
 2s0@
1
A; ð2:4Þ
where NA is the aperture number and n the refractive index.
Further assuming an overall transmittance topt(l) of
the entire optical set-up, a measuring spectral bandwidth
Dlem, and a spectral sensitivity (response) hdet(l) of the
detector, one finally gets the photoelectron flux fim (in
photoelectrons s21 molecule21) in the image plane taking
into account that the energy of a photon with wavelength l
is 1.987  10216/l J  2  10216/l J:
Fim ¼ 1016Qðlexc;lÞ  ½IexcsAðlÞ  ½qðlÞDlem
 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 NA
n
 2s0@
1
A  toptðlÞhdetðlÞ l4
 
; ð2:5Þ
with quantities between brackets having to be evaluated by
integration over the entire spectral range. As an example, a
xenon lamp source delivering 25 W cm22 at the specimen
and a 63 objective with numerical aperture NA ¼ 1.3
result in the emission of 25 photoelectrons s21 molecule21
provided Q(lexc, l) is large.
There are various techniques for recording luminescence
microscopy images and for improving the contrast and/or
the resolution. A commonly used one is confocal microscopy
in which conventional wide-field illumination is replaced
by spot laser illumination. A scanning unit is inserted
between the dichroic mirror and the objective, and allows
the illumination of successive points on the sample. In
addition, a pinhole is introduced in front of the detection
assembly for eliminating out-of-focus light rays. The name
‘confocal’ stems from the fact that only light emitted very
close to the focal plane in the sample can be detected. The
set-up results in increased optical resolution, though to the
cost of signal intensity so that reconstructed two- or three-
dimensional images require long exposure times. Confocal
microscopy is now often combined with multi-photon exci-
tation which protects live samples from photodegradation
by irradiation in the NIR instead of in the visible spectral
range; this also results in deeper penetration of the excitation
light into the sample [34].
A major problem affecting luminescence microscopy is
that both organic and inorganic chromophores are ubiquitous
in nature; UV or visible excitation therefore provokes an
intense luminescence stemming from the sample and its con-
tainment. This so-called autofluorescence severely obscures
background
fluorescence
phosphorescence
time
delay
time
acquisition
time
repeat time
Iem
excitation
pulse
t0 tf
t2t1
excitation
pulse
Figure 2. Principle of time-resolved luminescence and definition of essential
parameters.
Table 1. Rounded proportions (%) of the total emission intensity as a
function of delay (t1) and acquisition (t2) times for a normalized single-
exponential luminescence decay with lifetime t and B ¼ 0; see equation
(2.6). Shading points to ‘ideal’ conditions.
t1/t!
t2/t
0.0 0.1 0.2 0.5 1.0 2.0
1 63 54 45 24 0 0
2 87 77 68 47 23 0
3 95 86 77 56 32 9
4 98 89 80 59 35 12
5 99 90 81 60 36 13
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of filters and dichroic mirror may reduce the problem, but it
never eradicates it. This difficulty can be circumvented if
pulsed excitation is used and if images are produced based
on the differences in exponential decays of the luminescent
stain and the autofluorescence. In the case of organic fluoro-
phores, this is usually achieved by means of time-correlated
single-photon counting with resolution down to a few picose-
conds or by phase modulation when fluorescence lifetimes
are determined in the frequency domain by phase-modulated
detection. However, the instrumental set-up is relatively
sophisticated, and a way must be found for transferring
rapidly all of the data stored in the camera [35], so that
another solution is emerging: luminescence imaging with
phosphorescent bioprobes. Autofluorescence occurs in a
short span of time (typically in the nanosecond range), so
that simple time-resolved (or time-gated) detection can be
applied. The microscope is then operated in time domain
and detects only the longer time-scale events. The principle
of this powerful technique is outlined in figure 2.
Pulsed illumination is achieved either by a pulsed light
source (flash lamp, laser) or by modulating a continuous light
beam with a chopper or a ferroelectric shutter. The detector is
gated, that is, turned on or off depending on the advancement
of the experiment. The initial pulse defines t(0); at that time,
the detector is off. Intense autofluorescence is generated, and
the detector is maintained off until it disappears (gate or
delay time). Phosphorescence from the luminescent probe
develops more slowly, and the detector captures it until it
fades out (acquisition time). At that point, the detector is
again shut off, and a new light pulse is shined onto the
sample, restarting the cycle. Referring to lanthanide luminescent
probes, the entire experiment lasts about 1–4 ms, so that light
measurement can be theoretically repeated up to approximately
500 times per second, although practically the repetition rate
depends on the characteristics of the pulsed source. Both
delay and acquisition times have to be chosen carefully in
order to maximize the SNR. For instance, a very long delay
time cuts out the most intense emission from thephosphorescent probe, and a very long acquisition time leads
to noise integration at the end of the decay. If the lumine-
scent probe decay is a single-exponential function, then the
phosphorescence signal intensity decreases as
Iem ¼ I0em  et=t þ B; ð2:6Þ
where t is the excited-state lifetime of the chromophore and B is
the background noise. Proportions of the total emission signal
measured versus gate and acquisition times are collected in
table 1. From these simulated data, it is clear that the delay
time should not be longer than 0.5 t, whereas detecting light
emitted after 3–4t does not bring much signal improvement.
Visible-emitting LnIII ions such as EuIII or TbIII have lifetimes
in the range 0.5–2.5 ms so that, ideally, t1 should be in the
range 50–250 ms and t2 in the range 1.5–7.5 ms. Because most
of the TRL microscopes used to date are modifications of
epifluorescence microscopes and are fitted with a combination
of a fast switching pulsed light-emitting diode and a chopper
[36], long acquisition times can be implemented. Reported win-
dows are, however, in the range 0.1–5 ms only, which explains
why actual improvements are less than predicted. Nevertheless
sizeable and bettering in SNR of the order of 20–30 times are
regularly reported [36,37].
Another point stemming from table 1 is that, ideally, the
delay and acquisition times should be adapted to the
decay time of the luminescent probe. This is not very easy
with chopper-fitted microscopes, because these times not
only depend on the rotation speed of the chopper but also
on the number of blades. Optimum working conditions
would therefore require changing the chopper wheel, depend-
ing on the luminescent stain, which is not very practical.
Microscopes are therefore usually fitted with chopper wheels
adequate for one class of lanthanide luminescent probes (e.g.
polyaminocarboxylates, with lifetimes around 600–700 ms).
There are other ways of continuously modifying the time
delay, some have also their drawbacks [31] but it seems that
a new generation of light-emitting diodes (SpectraLED from
Horiba) will impose themselves as adequate pulsed light
sources for phosphorescence lifetime measurements. These
low-cost light-emitting diodes deliver pulses tunable between
0.1 ms and several ms, cover the spectral range 355–1275 nm,
can operate at high repetition rates and have no afterglow,
which permits more reliable determination of lifetimes shorter
than 100 ms.
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Scheme 1. Hexadentate, ditopic ligand for the self-assembly of triple-stranded lanthanide helicates.
(a) (b)
Figure 3. (a) Molecular structure of [Tb2(L
C1)3] (H atoms are omitted for clarity). (b) Coordination polyhedron showing the slightly distorted tricapped trigonal
prismatic arrangement. (Reproduced with permission from Elhabiri et al. [46].)
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helicates
Piguet and collaborators reported in 1992 the first dinuclear
triple-stranded lanthanide helicate [Eu2(L
A)3]
6þ (scheme 1), a
true supramolecular entity, because the molecular framework
is stabilized by p-stacking interactions between the ligand
strands [38]. This opened the way to a new class of lanthanide
polynuclear and polymetallic complexes with extensions,
including heterobimetallic 4f–4f0 [39,40] and nd–4f [41,42]
complexes, as well as tri- and tetranuclear homometallic and
heterometallic entities, among others [42,43]. An interesting
feature is that the 2 : 3 helicates are quite stable in organic sol-
utions despite an initially large Coulomb repulsion between
the two trivalent cations which lie about 9 A˚ apart; careful
thermodynamic considerations for 3d–4f and 4f–4f–4f
helicates, however, show that LnIII–LnIII repulsive energy
(700 kJ mol21) is largely compensated by solvation energy,
explaining the stability of the edifices [44]. A further develop-
ment took place in 1998 when water-soluble helicates
[Ln2(L
C1)3] were synthesized and shown to be quite stable,
with logb23 of the order of 26–30 [45]. Crystal structures
revealed triple-stranded helicates with nine-coordinate metal
ions (Ln ¼ Eu, Tb) well imbedded into the edifice and display-
ing a distorted tricapped trigonal prismatic coordination
geometry (figure 3).A detailed study of lanthanide-induced paramagnetic
shifts (Ln ¼ Ce, Pr, Nd, Sm, Eu, Tb, Er, Tm, Yb; diamagnetic
references with Ln ¼ Y, La, Lu) concluded that in D2O at pD
7.4–8.5, the solution structure is very similar to the solid state
structure, with an averaged D3 molecular symmetry [46].
The mechanism of formation of the [Eu2(L
C1)3] helicate has
been established and is depicted in figure 4 [47]; in any case,
i.e. in the presence of an excess of ligand or of metal ion, it
goes through a crucial 2 : 2 pre-helicate; the crystal structure
of such an intermediate, [Eu2(CF3SO3)4(H2O)2(L
B)2]
2þ, reveals
a side by side positioning of the ligand strands, each ligand
being coordinated to two EuIII ions located on the same side
[48]. The 2 : 2 intermediate is very stable towards dissociation
of either EuIII or (LC1)22 but it reacts very fast with the third
ligand strand which wraps around the two ions, giving birth
to the final triple-stranded helicate. The overall formation of
the dinuclear helicate is complete after a few seconds.
In the triple-stranded helicates, the two metal ions are well
protected from water interaction, hence leading to luminescent
entities with quantum yields in water of 0.5+0.01% for SmIII
[49], 24+2 and 1.2+0.1% for EuIII and TbIII, respectively
[43] and 1.8+0.2% for YbIII in D2O [50]. Further considering
that the edifices are potentially chiral—M and P CrIII–LnIII
helices have been isolated [51]—and that 4f–4f0 helicates can
be obtained in organic media [39,40], hinting to the possibility
of having dual emitting helicates or edifices with optical/
[Eu(LC1)]+ [Eu(LC1)2]– [Eu(LC1)3]3–
N
N
N
N
N
N
HO2C
II
H2L
C1
CO2H
(LC1)2–
(LC1)2–(LC1)2–
(LC1)2–
[Eu2(LC1)]4+ [Eu2(LC1)2]2+ [Eu2(LC1)3]
Eu
Eu Eu
Figure 4. Mechanism of the self-assembly of [Eu2(L
C1)3] in water. (Reproduced with permission from Elhabiri et al. [47].)
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Figure 5. Distribution diagram for [H2L
C2]t ¼ 100 mM. (Reproduced with per-
mission from Chauvin et al. [53].)
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providing such helicates as probes for cell imaging. To this
end, solubility in water and lipophilicity have been improved
by grafting short polyoxyethylene chains either on the imida-
zole units (H2L
C3 [52]) or in the four-position of the pyridine
units (H2L
C2 [53]). The best results have been obtained with
the latter and because extending the chain to six (CH2–CH2–
O) units in H2L
C20 did not bring notable improvements [54]
we restrict the discussion to [Ln2(L
C2)3] helicates.
The polyoxyethylene-fitted ligand H2L
C2 self-assembles
in water at pH 7.4 (Tris–HCl 0.1 M) with LnIII in the same
way as H2L
C1 yielding triple-stranded helicates with logb23
equal to 24.9+ 0.4, 25.5+ 0.4 and 26.3+ 0.4 for LaIII, EuIII
and LuIII, respectively. Other detected species include 1 : 3
and 2 : 1 complexes. The speciation diagram for EuIII is
shown in figure 5 for a total ligand concentration of
100 mM. At stoichiometric ratio, the helicate represents 95%
of the species in solution (97% if the ligand concentration is
increased to 450 mM), that is 2.5% less compared with
H2L
C1; however, most of the remaining EuIII is complexed
in minor species, so that the concentration of free EuIII,which could be cytotoxic, is negligible. When it comes to
bioprobes, not only the thermodynamic stability at physiologi-
cal pH, but also the kinetic inertness and the effect of pH are
important. These parameters have been tested by monitoring
the total EuIII luminescence intensity versus time after addition
of 100 equivalents of EDTA, diethylenetriaminepentaacetic acid
(DTPA), citrate, L-ascorbate or ZnII, or by varying the pH in the
3–10 range. No change in intensity occurred in most cases,
the only exceptions being 10% decreases in the presence of
DTPA and ascorbate and a 15% decrease in the presence
of ZnII [49]. This clearly points to the helicate being more
stable than the EDTA complex and of stability comparable
with that of the DTPA complex (note that [Gd(DTPA)]2 is
used as contrast agent in magnetic resonance imaging of
humans). Further experiments within the frame of the use
of [Eu2(L
C2)3] as a sensitive analytical probe for DNA showed
that CoII and CuII in 1000-fold excess substantially destroy
the helicate [55], but the concentrations used are orders of
magnitude larger than those found in living organisms.
In the absence of crystal structure, the symmetry of
[Eu2(L
C2)3] was probed by high-resolution luminescence
spectroscopy at low temperature, in frozen Tris–HCl/glycerol
(9/1 v/v): the emission spectrum (figure 6) is characteristic of a
species with slightly distorted trigonal symmetry as shown by
the 31 cm21 splitting of the E component of the 5D0! 7F1 tran-
sition, and the faint and unique band corresponding to the 5D0
! 7F0 transition (fwhh¼ 17 cm21). Introduction of the substi-
tuent in the four-position of the pyridine rings does not
influence much the photophysical properties of the EuIII heli-
cate with respect to [Eu2(L
C1)3], but the electron attractive
substituent pushes the ligand states towards slightly higher
energy and [Tb2(L
C2)3] becomes notably luminescent, with a
quantum yield reaching 11%, whereas the SmIII and YbIII heli-
cates have much smaller quantum yields (table 2), but can
nevertheless be used as bioprobes (vide infra).
As a conclusion, the chemical and physical properties of
the [Ln2(L
C2)3] helicates perfectly fulfil the requirements for
luminescent bioprobes operating in aqueous solution in the
pH range 3–10 (some organelles have pH as low as 2!).
Table 2. Quantum yields and lifetimes of the metal excited states for
[Ln2(L
Ci)3] helicates (i ¼ 1–2) in water at pH 7.4 [49].
helicate QLnL ð%Þ tobs (ms)
[Sm2(L
C1)3] 0.5+ 0.05 42+ 0.4
[Eu2(L
C1)3] 24+ 2 2400+ 100
[Tb2(L
C1)3] 1.2+ 0.2 50+ 0.5
[Yb2(L
C1)3] 1.8+ 0.2
a 40+ 2a
[Nd2(L
C2)3] n.a. 0.21+ 0.02
[Sm2(L
C2)3] 0.38+ 0.06 30.4+ 0.4
[Eu2(L
C2)3] 21+ 2 2400+ 100
[Tb2(L
C2)3] 11+ 2 650+ 20
[Yb2(L
C2)3] 0.15+ 0.03 4.40+ 0.07
aMeasured in D2O.
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Figure 6. High-resolution emission spectrum of [Eu2(L
C2)3] at 10 K, in frozen Tris–
HCl/glycerol (9/1 v/v) under ligand excitation at 341 nm. (Reproduced with per-
mission from Chauvin et al. [53].) (Online version in colour.)
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are also in line with this function, an assessment which is
described in §4.4. In vitro cell imaging
The cytotoxicity of the helicates has been tested by incubating
several cell lines in the presence of various concentrations of
EuIII chelates and measuring the cell viability by WST-1
assays. These assays concerned Jurkat human T leukaemia,
5D10 mouse hybridoma, MCF-7 human breast carcinoma
and HeLa cervical adenocarcinoma cell lines. They were con-
ducted for [Eu2(L
C1)3] [49], [Eu2(L
C2)3] [53] (figure 7) and
[Eu2(L
C3)3] [52] with all cell lines and with HeLa cells only
for [Eu2(L
C20)3] [54] and [Eu2(L
C5)3] [57]. No cytotoxicity
was evidenced up to 500 mM; owing to its smaller solubility,
[Eu2(L
C1)3] was tested only up to 125 mM but was also found
to have no influence on cell growth and morphology [49]
(figure 7b).
Internalization experiments have been conducted with
helicates with (LC1)22 [49] and (LC3)22 (Ln¼ Eu) [52], (LC2)22(Ln¼ Sm, Eu, Tb, Yb) [53,56] as well as (LC5)22 (Ln ¼ Eu)
[57]. All of the tested helicates penetrate into the various
cell lines without altering their morphology. Three different
imaging experiments are shown in figure 8. Luminescence
and confocal images have been recorded according to the
experimental conditions described in figure 9, which depicts
the transmission of the various filters and of the dichroic
mirror in regard of the absorption and emission spectra of
[Eu2(L
C2)3]: a careful combination of these optical components
leads to images with good contrast even for confocal images
despite the very small residual absorption at 405 nm; however,
one notes for the latter a sizeable background emission at zero
concentration of the helicate. This disadvantage vanishes under
TRD mode which allows one to identify EuIII luminescence
after a short incubation time of 15 min only and with better res-
olution. Images could be recorded with a helicate concentration
as low as 5 mM. The internalization mechanism has been inves-
tigated by means of several co-staining experiments [49,56].
The chelates are first taken up in isolated vesicles which diffuse
into the cytoplasm and eventually gather around the nucleus,
on one side of the cells. The vesicles have sizes ranging from
0.5 to 2 mm. The helicates remain in the vesicles, that is, they
do not diffuse into the cytoplasm or nucleus. Co-localization
experiments with several organic dyes led to the conclusion
that the majority of [Eu2(L
C2)3]-stained vesicles are localized
within the endoplasmic reticulum and not in the Golgi appar-
atus. Estimation of the intracellular concentration by the
DELFIA luminescence technique gave about 5  108 helicates
per cell, or between 0.18 and 0.30 mM, corresponding to a
remarkable concentration effect, because cells for this exper-
iment were incubated in the presence of 25 mM of helicate only.
Leakage of the helicates out of the cells was determined
with time-lapse experiments and found to be slow as indicated
by an approximately 30% loss of luminescence intensity after
24 h. Furthermore, helicates with SmIII, TbIII and YbIII behave
in the same way as [Eu2(L
C2)3]. Because the luminescence life-
times are different, some time-based discrimination is therefore
feasible, in addition to wavelength discrimination.
The excitation maximum of [Eu2(L
C2)3] at 330 nm is how-
ever not optimum, because this wavelength can be potentially
phototoxic for some cells. Attempts have therefore been made
to shift the excitation wavelength more into the visible. A first
solution was to modify the ligand by fusing pyridine rings on
the benzimidazole moieties, resulting in H2L
5 (scheme 1). The
resulting self-assembled helicates retain high thermodynamic
stability, non-cytotoxicity, and they also localize in the endo-
plasmic reticulum. Interestingly, their absorption spectra
display a low-energy intense band with maxima at 350 and
365 nm (log 1 ¼ 4.90 and 4.82, respectively; figure 10a), so that
cell experiments can be conveniently performed with excitation
at 365 nm, despite a lower quantumyield of 9%.Moreover, con-
focal microscopy with excitation of [Eu2(L
C5)3] at 405 nm gives
brighter images than [Eu2(L
C2)3]. The improvement is, however,
less than expected: at the latter excitation wavelength,
[Eu2(L
C5)3] is much more luminescent than [Eu2(L
C2)3]; how-
ever, the number of helicates taken up in the cells is 30%
lower compared with [Eu2(L
C2)3], which reduces the previous
advantage. This demonstrates that all thermodynamic, photo-
physical and biochemical parameters intervene in defining the
efficiency of a given luminescent bioprobe.
Another solution to lengthening the excitation wave-
length is to turn to two-photon excitation. The two-photon
absorption cross section of [Eu2(L
C5)3] was found to be
% live cells 120 0 h
(b)(a)
24 h
[Eu2(LC2)3]
100
80
60
40
20
0 0 125 250 500
10 µm
µM
HeLaMCF-75D10Jurkat
Figure 7. (a) Results of WST-1 viability assays for various cell lines incubated for 24 h at 378C in the presence of various concentrations of [Eu2(L
C2)3]. (Reproduced
with permission from Chauvin et al. [53].) (b) Phase contrast images of HeLa cells exposed to 100 mM of [Eu2(L
C2)3]. (Adapted from [56].)
125 µM 
0 µM
7 h
7 h
7 h
125 µM 7 h
0.25 h 2 h 1 h 
100 µM 100 µM 100 µM 
125 µM (a)
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(c)
Figure 8. Imaging of HeLa cells incubated at 378C with [Eu2(L
C2)3]. (a) Bright-field and luminescence microscopy (lexc ¼ 330 nm; exposure time ¼ 60 s). (Unpub-
lished data, 2007.) (b) Confocal microscopy (lexc ¼ 405 nm). (Adapted from [58].) (c) Time-resolved microscopy (lexc ¼ 330 nm, time delay ¼ 100 ms; gate
time: 600 ms; exposure time: 30 s). (Adapted from [56].)
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spectrum (755 nm) and both one-photon and two-photon
excitation spectra superimpose perfectly. Despite the small
cross section (some EuIII complexes have cross sections up
to 775 GM [59]), due to the fact that the ligand is not opti-
mized for multi-photon absorption, well-contrasted images
of HeLa cells incubated with 200 mM [Eu2(L
C5)3] could be
observed under Ti–sapphire laser excitation at 750 nm [60].
The main drawback of the dinuclear helicates as lumines-
cent bioprobes is their intrinsic lack of selectivity: all tested
cell lines are stained in the same way. In principle, one may
think that the global charge of a metal complex and/or its
lipophilicity can drastically influence its cell cytotoxicity, per-
meability and localization. We have therefore investigatedwhether derivatization of the pendant polyoxyethylene moi-
eties and/or modification of the coordination unit would
introduce some selectivity or at the least modify the localiz-
ation of the helicates within the cells. To this end, the
ligands shown in scheme 2 have been synthesized. Similar
to H2L
C2, they self-assemble with LnIII ions to yield stable
dinuclear helicates the photophysical properties of which
are modulated by the substituents [61].
These ligands allowed us to test the influence of (i) the
coordinating group, phosphonate in [Eu2(L
POEt)3] [62] versus
carboxylate in [Eu2(L
C2)3], (ii) the polarity of the pendant
arms, OH substituent in [Eu2(L
C2CH2OH)3] versus OMe termi-
nal function in [Eu2(L
C2)3]) and/or (iii) the overall charge
of the probe by using a negatively charged complex
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Figure 10. (a) Absorption spectra of [Eu2(L
C2)3] and [Eu2(L
C5)3]. (Reproduced with permission from [53,57].) (b(i)) Time-resolved luminescence images (lexc
365 nm) of HeLa cells incubated 6 h at 378C with 5 and 25 mM [Eu2(L
C5)3]; (b(ii)) confocal microscopy images (lexc 405 nm) of HeLa cells incubated 18 h at
378C with 31 and 125 mM [Eu2(L
C5)3]. (Adapted from [57].) Copyright &2009 Wiley-VCH.
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C2COOH-2H)3]
62 or a potentially positively charged one
[Eu(LC2NH2þ2H)3]6þ: indeed, the pH of some endosomal com-
partments can reach values as low as 2 and, because the pKb of
the terminal amine is around 7.0, it is expected that it will be
protonated at such a low pH value. The phosphonate helicate
[Eu2(L
POEt)3] was chosen in place of the polyoxyethylene-
fitted one because its quantum yield is much larger (25%
versus only 2.5%) [62]. All the helicates bearing different coor-
dinating and terminal groups permeate into HeLa cells and
stain the cytoplasm. Co-staining experiments with LysoTracker
blue show that most helicates are present in secondary
endosomes and lysosomes, irrespective of their polarity or
overall charge. A similar conclusion has been reached from
an extensive study of more than 60 cyclen-based lanthanide
luminescent bioprobes; however, for these stains, modification
of the nature of the polyaromatic substituent on the cyclen fra-
mework led to widely different cell-penetrating properties,
localization and cytotoxicity because these substituents are
recognized by protein association [14,30,63–65]. As a con-
clusion, specificity for the dinuclear luminescent probes has
to be built via immunochemical reactions.
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Figure 11. Formation of a bioconjugate between [Eu2(L
C2)3]@SiO2/NH2 and IgG. (Reproduced with permission from Eliseeva et al. [66].)
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5.1. Bioconjugated nanoparticles
As a first attempt to gain selectivity, [Eu2(L
C2)3] helicates have
been imbedded into –NH2 derivatized silica nanoparticles.
The resulting nanoparticles, [Eu2(L
C2)3]@SiO2/NH2, display a
larger quantum yield (28%) than the parent helicate and can
be conjugated with streptavidin or with monoclonal antibodies
(mAbs) [66]. Immunoassays with the nanoparticles derivatized
with the goat anti-mouse immunoglobulin G (IgG) mAb
(figure 11) were able to detect 15 ng ml21 of the biotinylated
5D10 antibody on a streptavidin-coated plate with a SNR of
100. However, non-specific binding of the derivatized nanopar-
ticles limits the sensitivity of the analysis. Immunocytochemical
assays involving recognition of mucin-like proteins expressed
on breast cancer MCF-7 cells by the 5D10 mAb led to specific
luminescence signals with a SNR approximately 20% larger
than the one obtained with the bioconjugate of [Eu2(L
C2COOH)3]
with IgG. In parallel to these assays, we have expanded our
quest for biospecificity allied with high detection sensitivity
by moving to laboratory-on-a-chip experiments which are
described in §5.2.
5.2. Construction and test of a laboratory-on-a-chip
device for detecting cancerous cells
Breast cancer accounts for almost one-quarter of cancers
affecting women, hence the importance of developing sensi-
tive detection methods. The long-living Michigan Cancer
Foundation 7 (MCF-7) cell line, discovered in 1970, is a
major cell line used in many studies of this carcinoma.
MCF-7 cells can be targeted with use of the 5D10 mAb
which reacts with most invasive ductal adenocarcinomas.
The diagnostic value of this mAb was established in studies
showing that its response to human breast carcinomas corre-
lates with the DNA ploidy status (¼the number of sets of
chromosomes in the nucleus) of tumour cells [67]. We have
therefore developed an indirect immunocytoluminescent
assay in which the biotinylated 5D10 mAb is bound to its
antigen expressed on the cell membrane and subsequently
linked to the avidin-conjugated lanthanide luminescentlabel. Alternatively, a direct assay can also be conducted
in which the detection (primary) mAb is bioconjugated to
the luminescent lanthanide helicate. For speeding up the
experiment and also, and most importantly, in an effort to
reduce cost by reducing the volume of required (expensive)
bioconjugates, a simple microfluidics device has been
designed which features a 200 mm wide zigzag channel
generated by a replica-moulding technique into a block of
biocompatible polydimethylsiloxane (PDMS). The device is
connected to high precision peristaltic pumps (figure 12).
To test the device, two types of experiments have been
implemented (figure 13). In the first one, MCF-7 cells were
grown in the fibronectin-coated microchannel and detected in
time-resolved mode via the 5D10 mAb test using a commer-
cial lanthanide luminescent probe, Eu-W8044 (scheme 3),
with a quantum yield of 23.6(5)% and Eu(5D0) lifetime
equal to 1.42(2) ms. The attained limit of detection with this
bioconjugate (EuB1) was 0.6 mg ml21, that is 2.3-fold smaller
compared with the assay performed with the conjugate of
fluorescein isothiocyanate (FiB3), a common reactant for this
type of experiments.
MCF-7 cells express several characteristic receptors
among which the oestrogen receptor (ER) expressed by the
nucleus membrane and the human epidermal growth factor
Her2/neu expressed by the cell membrane are particularly
important. These two receptors are routinely used in clinical
practice, having an established role in predicting tumour
response to hormone therapy and to immunotherapy with
the mAb trastuzumab used in cancer treatment. The second
experiment therefore consisted of detecting these two recep-
tors in three breast cancer tissues (figure 13b) which were
incubated with anti-Her2/neu IgG followed by biotinylated
anti-IgG and Eu-W8044-labelled avidin (indirect assay) or
with anti-ER IgG followed by Eu-W8044-labelled anti-IgG
(direct assay). The cell nuclei were subsequently stained
by 40,6-diamidino-2-phenylindole. The results shown in
figure 14 correlate very well with the clinical analyses [68].
Thepositive outcomeof these experiments encouragedus to
bioconjugate the [Ln2(L
C2COOH)3]
62 (Ln ¼ Eu, Tb) helicates and
to use the resulting conjugates as luminescent bioprobes for
detecting the ER and Her2/neu receptors, as described in §5.3.
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Figure 13. Cross sections of the microfluidic chip used for the study of (a) cancer cells seeded in the microchannel and (b) a section of human breast cancer tissue.
Principles of (c) indirect and (d ) direct immunocytoluminescent assays. (Adapted from [68].) Copyright &2009 The Royal Society of Chemistry.
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Figure 12. (a) Microfluidic device installed on the luminescence microscope with the pumping system on the right-hand side. (b) Detail of the zigzag channel.
Photographs taken in the author’s laboratory.
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Figure 14. On-chip immunohistochemical detection of Her2/neu (a) and ER (b) in three human breast cancer tissue samples (see text for details). The results of the clinical
analyses are given at the bottom:2, negative; 3þ, strongly positive;þ80%, positive. (Adapted from Song et al. [68].) Copyright&2009 The Royal Society of Chemistry.
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Figure 15. (a) Superposition of the MALDI-TOF mass spectra between 45 and
75 kDa of avidin ( patterned spectrum) and EuB2 (red line). (b) Absolute
emission intensity of EuB1 (orange squares), EuB2 (red triangles) and FiB3
(green squares) as a function of the biotinylated rabbit anti-streptavidin
(a-SA-B) antibody concentration. (Reproduced with permission from Fernan-
dez-Moreira et al. [69].)
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biomarkers expressed by cancerous cells
The dinuclear [Eu2(L
C2COOH-2H)3]
62 helicate was conjugated
to avidin in a two-step reaction. First, the carboxylic acid func-
tions of the pendant arms were activated with a mixture of 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide/1-hydroxy-2-
nitrobenzene-4-sulfonic acid in dry dimethylsulfoxide. The
protein dissolved in phosphate-buffered solution (pH 8.2)
was then added, and quenching of the reaction by ethylamine
hydrochloride yielded the desired luminescent conjugate
EuB2 presenting a statistical repartition of its six arms fitted
either with a carboxylate or with carboxamides (CONEt or
CON-avidin moieties). On average, 3.2 helicates were found
to be bound to avidin, and the covalent nature of this inter-
action is ascertained by matrix-assisted laser desorption/
ionization time of flight (MALDI-TOF) mass spectral data
which clearly show a shift of about 3 and 5.9 kDa for two
avidin fragments (the helicate has a molar mass of about
3 kDa; figure 15a). The photophysical properties of EuB2
are very similar to those of the parent [Eu2(L
C2)3] helicate
(table 2), except for the quantum yield which decreases to
9.3%. Owing to the large molar absorption coefficient of the
ligands though, the luminosity of this probe remains quite
good with 1Q ¼ 7560 M21 cm21. Bioaffinity assays were per-
formed with EuB1, EuB2, and, for comparison purposes, FiB3
in the detection of biotinylated rabbit anti-streptavidin (a-SA-B).
The results reported in figure 15b show the superiority of the
Eu-labelled bioconjugates over the fluorescein isothiocyanate
one, the detection limits of a-SA-B being 1–2.5 ng ml21 for the
EuIII conjugates versus 34 ng ml21 for the all-organic stain.
Similarly, indirect immunocytochemical assays performed
on MCF-7 cells revealed that the detection of the mucin-like
protein expressed by these cells and evidenced via the biotiny-
lated 5D10 mAb itself recognized by the bioconjugates EuB1,
EuB2 and FiB3 is achieved with better selectivity by the lantha-
nide bioprobes (SNR¼ 6–7) compared with the organic one
(SNR ¼ 2). The better selectivityof the EuIII bioconjugates is con-
firmedbystatistical analysis of luminescencemicroscopy images
[69]. When MCF-7 cells were grown in the microchannel, the
detection limit (DL) is larger, but the lanthanide probes remainmore sensitive with DL ¼ 0.6–0.7 versus 1.4 mg ml21. Finally,
the specificity of the 5D10 assay for MCF-7 cells grown in the
microchannel is illustrated in figure 16 by TRL microscopy: no
EuIII emission is detected when no or the wrong mAb is used
or when HeLa cells are reacted with the 5D10 antibody.
MCF-7, no Ab MCF-7, anti-mycoplasma HeLa, biotinyl-5D10 MCF-7, biotinyl-5D10
50 µm
(a)
(b)
Figure 16. On-chip immunocytochemical detection of the mucin-like protein expressed on MCF-7 cells grown in the 200 mm microchannel by biotinylated 5D10
monoclonal antibody and the EuB2 bioconjugate. (a) Bright-field images. (b) Time-resolved luminescence images. Columns: negative controls (no mAb, column 1;
a-myco-B antibody, column 2; and HeLa cells with 5D10-B, column 3) and positive test with MCF-7 cells and biotinylated 5D10, column 4. (Adapted from Fer-
nendez-Moreira [69].) Copyright &2010 The Royal Society of Chemistry. (Online version in colour.)
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expressed in the sections of human breast cancerous tissues
has been performed in the microfluidic system similar to
what is shown in figure 14, except that both receptors were
detected simultaneously by taking advantage of the spectral
versatility brought by red-emitting EuIII and green-emitting
TbIII bioconjugates. However, when performing the indirect
immunohistochemical assays on breast cancer tissues, using
the biotin–avidin system, we were confronted with a high
intracellular background signal, which can likely be attribu-
ted to the intracellular expression of biotin, often observed
in cancer tissues. Therefore, two new bioconjugates have
been developed: EuB4, a EuIII-labelled goat anti-mouse IgG
Ab, and TbB5, a TbIII-labelled goat anti-rabbit IgG Ab. The
principle of the indirect immunohistochemical assays is
described in figure 17a and is alike for both receptors: a
primary antibody selective for the targeted receptor is recog-
nized by a secondary antibody conjugated to the chosen
lanthanide helicate [Ln2(L
C2CO2H)3].
Again, TRD eliminates background noise, yielding highly
contrasted images (figure 17b). The Her2/neu biomarkers
expressed on the cancerous cell surface are illuminated by
TbB5, whereas the ER biomarkers located within the nuclear
membranes of the cancerous cells are evidenced with EuB4.
The results are in complete agreement with those obtained
in the clinical laboratory using classical immunohistochemis-
try settings, but were achieved in only 20 min versus the 2 h
required for the classical protocol and with five times less
reactants. Further analyses of about 50 samples confirmed
the match between clinical and TRL analyses. Therefore,
this might be good news for health insurances if this new pro-
tocol can be effectively implemented, i.e. officially validated.5.4. Further developments
In order to speed up the previous immunohistochemical
detection, another microfluidic device has been designed fea-
turing arrays of microchannels and a 2.5-fold larger detection
area. The flush time of the device is considerably shortened,
as shown in figure 18a: the reactant filling the cell can beflushed (e.g. by a buffer solution) in 2.5 s, its concentration
dropping from 1 to 10212 M. With the new analysis chamber
which is also easier to assemble and disassemble, the total
time of analysis of the Her2/neu and ER biomarkers can be
completed for each biomarker in less than 5 min, with only
60 ml of reagents and 120 ml of buffer [70].
A common and time-consuming task in biology labora-
tories is the separation of targeted cells from heterogeneous
cell mixtures. Frequently used methods are fluorescence-
activated and magnetically activated cell sorting, and these
techniques have been adapted to microfluidic environments.
However, the continuous flow operation of fluorescence-
activated cells bearing an adequate fluorescent tag is not
easily compatible with the retention of the targeted cells
inside the microfluidic device. On the other hand, in immu-
nomagnetic cell separation, the cells of interest, adequately
marked with a magnetic tag, can be retained by activating
an external magnetic field. After separation, the cells may
be transported to other sites of the microfluidic device for
further analysis and/or treatment. The magnetic tag can,
however, interfere during these subsequent assay steps and
a label-free separation is more desirable. In particular, immu-
noaffinity-based cell separation represents an interesting
method applicable to microfluidic devices.
The tools developed in our laboratories and described
above have been combined to produce a protocol in which
cell separation, amplification (cell culture) and specific detec-
tion are merged in a single set-up. The principle is illustrated
in figure 19 and in the following description. First, streptavidin-
coated magnetic beads were directly patterned inside a
sealed microfluidic channel (width 200 mm, height 100 mm,
length 25 mm) by rapid magnetic-field-assisted electrostatic
self-assembly (figure 19a). The beads, which formed 50 mm
wide stripes with a pitch of 40 mm, were then coated with bio-
tinylated 5D10 mAb and biotinylated fibronectin (figure 19b)
resulting in two-thirds of the bead surface being covered
with 5D10 and the remaining surface with fibronectin. The
separation concept has been tested with a mixture of MCF-7
and Jurkat cells (figure 19c): a single filling step of the micro-
channel is sufficient to capture all MCF-7 cells, whereas
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Figure 17. (a) Principle of the two indirect assays for the detection of the Her2/neu (left) and ER (right) receptors expressed by human breast cancer cells.
(b) On-chip immunohistochemical detection of Her2/neu and ER in a breast cancer tissue sample. (Adapted from Fernandez-Moreira [69].)
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Figure 18. (a) Flush time of the second-generation microfluidic chamber. (b) Analysis of biomarkers expressed by human breast cancer tissue. (i) Bright-field image;
time-resolved luminescence images of the Her2/neu receptors illuminated by the TbIII bioconjugate (ii) and of the ER receptors detected with the EuIII bioconjugate
(iii); same experimental conditions as for figure 17. (Adapted from Ciftlik et al. [70].) Copyright &2010 The Royal Society of Chemistry.
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Figure 19. Schematic of the concept of specific capture of MCF-7 cells from a cell mixture on self-assembled beads micropatterned inside a microfluidic channel. See
text for explanation. (Adapted from Sivagnanam et al. [71].) Copyright &2010 American Chemical Society.
(b)(a)
Figure 20. (a) Bright-field image showing MCF-7 cells captured and cultured on the patterned beads inside the microchannel device (scale bar, 40 mm). (b) Time-
resolved luminescent microscopy image showing the presence of the 5D10 biomarkers on the surface of the MCF-7 cells, thanks to the Eu-8044-mAb conjugate.
(Adapted from Sivagnanam et al. [71].) Copyright &2010 American Chemical Society.
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cells were subsequently incubated during 4 h (figure 19e)
before being detected in time-resolved mode with the com-
mercial EuIII-containing bioconjugate featured in scheme 3
(figure 19f ). The resulting image is shown in figure 20.6. Conclusion
The work described in the preceding sections represents only a
tiny part of the present efforts devoted to the development of
luminescent lanthanide bioprobes displaying high specificity.
These efforts are relying on all aspects of lanthanide photophy-
sics, and both coordination compounds and inorganic materials
are being investigated, as outlined in §1. The availability of sen-
sitive spectroscopic instrumentation working in the visible and
NIR spectral ranges, as well as remarkable improvements insynthetic and surface chemistry allow chemists and biochemists
to concentrate on solving specific problems without too many
technical restrictions, except for intrinsic physical limits. One
of these limits in optical imaging is the penetration depth of
light in the tissues. In principle, this may be overcome using
NIR light, for example, UCNPs; however, loss of lateral
resolution has been observed beyond 600 mm [72], so that
improvements are still required.On the other hand, thediversity
of luminescent lanthanide ions and compounds thereof is a
major asset for tailoring specific analyses using lanthanide bio-
probes. There is no doubt that lanthanide bioprobes will
remain strong competitors in luminescent immunoassays and
that they will add valuable tools to the panoply of techniques
available to biochemists and medical doctors for both in vitro
and in vivo bioimaging. Their assets, multiplexing possibility,
small photobleaching, non-overlapping excitation and emission
spectra, long excited state lifetimes, and easy amenability to
rsfs.royalsocietypublishing
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 on August 23, 2013rsfs.royalsocietypublishing.orgDownloaded from bioconjugation form aunique and highly useful set of properties
which cannot be claimed by other bioprobes. In particular,
developers in the field are using lanthanide probes in combi-
nation with other techniques to produce multi-modal labels
each property of which fulfils a specific task. What is also clear
is that the full array of diagnostic tools, organic markers, QDs,
transition metal and lanthanide bioprobes, as well as biochemi-
cal markers, will be necessary to cope with the ever increasing
demand for high-quality analyses and images in the biosciences.Acknowledgements. The author is indebted to all his collaborators for the
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